Terminalia

Terminalia: A Comprehensive Reference

1. Identity and Botanical Classification

Genus Overview

Terminalia is a genus of large trees in the flowering plant family Combretaceae, comprising nearly 300 species distributed in tropical regions of the world. The genus name derives from the Latin word terminus, referring to the fact that the leaves appear at the very tips of the shoots. It is the second largest genus in the family Combretaceae. The genus is distributed mainly in southern Asia, the Himalayas, Madagascar, Australia, and the tropical and subtropical regions of Africa.

The bark of Terminalia plants usually has cracks and branches tucked into layers. Most leaves are large and leathery, with solitary or clustered small green-white flowers. Their fruits are yellow, dark red, or black, typically drupes that are angular or winged. Some fruits are edible, highly nutritious, and possess medicinal values.

Principal Medicinal Species

Although several dozen species possess documented traditional or pharmacological use, the following three are most prominent in research and traditional medicine:

• Terminalia arjuna (Roxb. ex DC.) Wight & Arn. — commonly known as Arjuna. T. arjuna reaches approximately 30 m in height and has light-yellow flowers and cone-shaped leaves. It is used primarily for its bark.
• Terminalia chebula Retz. — known in Ayurveda as Haritaki, and in English as chebulic myrobalan or black myrobalan. T. chebula grows approximately 21 m in height and has white flowers and small, ribbed fruits. Other Terminalia species, including T. chebula, are primarily used for their fruits.
• Terminalia bellirica (Gaertn.) Roxb. — known as Bibhitaki or Bahera. T. bellirica has clustered oval leaves and greenish, foul-smelling flowers with brown, hairy fruit approximately the size of a walnut.

Other notable species include Terminalia catappa (Indian almond), Terminalia ferdinandiana Exell, most commonly known as the Kakadu plum or gubinge, a flowering plant in the family Combretaceae native to Australia, widespread throughout the tropical woodlands from north-western Australia to eastern Arnhem Land.

Common Forms and Preparations

Most research on T. chebula focuses on the fruit, especially whole fruit powder, aqueous extracts, hydroalcoholic extracts, and topical or oral health preparations made from the fruit. T. arjuna is used primarily for its bark, while other Terminalia species are primarily used for their fruits. Preparations across traditional systems include decoctions (bark or fruit boiled in water), powders of dried fruit or bark, pastes applied topically, and standardized aqueous or hydroalcoholic extracts used in modern research settings.

2. Traditional and Historical Use

Ayurvedic Medicine (India)

Arjuna bark has been used in the traditional Ayurvedic medical system for at least 3,000 years as a remedy for heart ailments, and T. chebula has been used as a digestive aid. T. arjuna has been used by Ayurvedic physicians in India for the treatment of various cardiovascular diseases, collectively referred to as hritroga.

A traditional Ayurvedic herbal combination dating back 5,000 years is a mixture of three herbs, two of which are Terminalia species: T. bellirica (for health-harmonizing qualities), T. chebula (to normalize body balance), and Emblica officinalis (for vitamin C content). This formulation is commonly known as Triphala and is used for its laxative, detoxifying, and rejuvenating effects.

T. arjuna has been traditionally used for its cardioprotective effects in Indian culture. T. bellirica has been used to treat diarrhea, scorpion stings, and cough. In Indian and Iranian traditional medicine, T. chebula is used to manage dementia, constipation, and diabetes.

The fruit of T. chebula is described as a mild laxative, stomachic, tonic, and antispasmodic. It is considered useful in ophthalmia, hemorrhoids, dental caries, and bleeding gums. Its paste with water is found to be anti-inflammatory and analgesic with purifying and wound-healing capacity. Its decoction is used as a gargle in oral ulcers and sore throat. Its powder is used as an astringent dentifrice in loose gums, bleeding, and ulceration. It is considered a digestive aid, liver stimulant, stomachic, gastrointestinal prokinetic agent, and mild laxative.

The deciduous tree Terminalia bellirica found in Southeast Asia is extensively used in traditional Indian Ayurvedic medicine for the treatment of hypertension, rheumatism, and diabetes.

Tibetan Medicine

T. chebula, referred to as the "king of medicine" by Tibetans, is often depicted in the extended palm of Buddha. Many species are used widely in traditional Chinese medicine, Tibetan medicine, and Indian Ayurvedic medicine practices. In Tibetan medicine (Sowa Rigpa), T. chebula (known as a-ru-ra) is considered one of the most important botanical medicines, and its image appears in classical thangka paintings depicting the Medicine Buddha.

Traditional Chinese Medicine

These are some of the most widely used medicinal plants in global ethnopharmacology, such as traditional Chinese, Tibetan, and Indian Ayurvedic medicine systems. In traditional Chinese medicine, T. chebula fruit rind (he zi) has historically been used for conditions including chronic diarrhea, dysentery, and respiratory ailments.

African and Australian Indigenous Use

Recent reports have highlighted the medicinal potential of species from Africa, Australia, and the Americas. Used as a traditional bush food and bush medicine for centuries, T. ferdinandiana fruit has especially high levels of vitamin C. As with many other Australian Terminalia species, T. ferdinandiana fruits and seeds have historical uses in the Aboriginal diet and as a medicinal plant. Australian Aborigines ate the fruit directly, used it to make a refreshing drink, and also used it to make edible jelly and gum.

Various species of the Terminalia genus are used in the form of herbal medicine and formulations for treatment of diseases including headache, fever, pneumonia, flu, geriatric conditions, cancer, memory improvement, abdominal and back pain, cough and cold, conjunctivitis, diarrhea, heart disorders, leprosy, sexually transmitted diseases, and urinary tract disorders.

3. Key Constituents and Active Compounds

Overview of Phytochemical Diversity

So far, about 39 species have been phytochemically studied, which led to the identification of 368 compounds, including terpenoids, tannins, flavonoids, phenylpropanoids, simple phenolics, and others. These include largely terpenoids, tannins, flavonoids, lignans, phenols, and glycosides.

Tannins (Hydrolyzable and Condensed)

Tannins represent the most pharmacologically significant chemical class across medicinal Terminalia species. The most abundant tannins in T. chebula fruit include gallic acid, ellagic acid, chebulic acid, chebulinic acid, punicalagin, terflavin A, corilagin, galloyl glucose, and tannic acid. Available flavonoids include quercetin, catechin, and others.

Gallotannins and ellagitannins are polymers found in the fruits of T. chebula. Gallotannins contain gallic acid esterified and bonded with the hydroxyl group of a polyol carbohydrate such as glucose. Ellagitannins are formed when oxidative linkage occurs in the galloyl groups in 1,2,3,4,6-pentagalloyl glucose. Ellagitannins differ from gallotannins in that their galloyl groups are linked through C–C bonds, whereas the galloyl groups in gallotannins are linked by depside bonds.

Chebulagic acid, a benzopyran tannin, is widely distributed in several plant families including the Combretaceae. In the Combretaceae family, chebulagic acid is a main constituent of the fruits of T. bellerica, T. chebula, and Emblica officinalis. Chebulinic acid, also known as 1,3,6-tri-O-galloyl-2,4-chebuloyl-β-D-glucopyranoside, is an ellagitannin found in the fruits of T. chebula or in the leaves of T. macroptera.

Triterpenes and Triterpenoid Glycosides

104 terpenoids including 86 triterpenes, 14 monoterpenes, and 4 sesquiterpenes have been reported from the genus Terminalia. The triterpenoids are mainly oleanane, ursane, and lupane types, and their glycosides. The arjuna tree accumulates bioactive triterpene glycosides (saponins) and aglycones (sapogenins) in a tissue-preferential manner. Oleanane triterpenes/saponins (derived from β-amyrin) with potential cardioprotective function predominantly accumulate in the bark.

The triterpenes arjun glucoside I, arjungenin, and chebulosides I and II have been reported in T. chebula. Various bioactive compounds, including triterpinoids, tannins, flavonoids, and minerals, have been isolated from the stem bark of T. arjuna.

Flavonoids and Phenolic Acids

Flavonoids such as luteolin, rutin, and quercetin, as well as tannins up to 30%, chebulic acid 3–5%, chebulinic acid 30%, tannic acid 20–40%, ellagic acid, gallic acid, ethyl gallate, punicalagin, terflavin A, and terchebin have been reported in T. chebula. Phenolic compounds identified by HPLC in ethanolic extracts of T. avicennioides, such as isorhamnetin, quercetin, and ferulic acid, are recognized for their antimicrobial and antioxidant properties.

Vitamin C — T. ferdinandiana

The fruits of T. ferdinandiana are empirically verified to contain ascorbic acid concentrations up to 3,150 mg per 100 g fresh weight, representing one of the highest recorded levels among edible plant materials and exceeding oranges by over 50-fold.

Other Constituents

Saccharides including D-glucose, D-fructose, quinic acid, and shikimic acid are also present in T. chebula fruit. The stem bark of T. arjuna contains high levels of antioxidant compounds, including glycosides, flavonoids, tannins, and inorganic minerals.

4. Established Mechanisms of Action

Antioxidant Activity

Analysis of T. chebula fruit extract shows that it contains phenolic compounds which are good scavengers of free radicals. It also exhibits anti-lipid peroxidation, anti-superoxide radical formation, and free radical scavenging activity. The methanolic extract has the greatest triterpenoid content and exhibits good antioxidant activity. T. bellirica extract showed DPPH radical scavenging activity (EC₅₀: 7.2 ± 1.2 μg/mL) and 15-lipoxygenase inhibitory activity, and significantly inhibited free radical-induced LDL oxidation compared to solvent control in vitro.

Anti-Inflammatory Mechanisms

Twelve isolated compounds from methanolic extract of T. chebula inhibited cyclooxygenase-2 (COX-2) and nitric oxide synthase (iNOS) in LPS-stimulated macrophages. Tannins such as 2,3,6-tri-O-galloyl-Beta-D-glucose and chebulinic acid and triterpenoids including arjunolic acid and arjunic acid decreased IC₅₀ values. The expressions of COX-2 and iNOS proteins were reduced from 54% to 70% and 33% to 37% at 50 µmol; these extracted compounds were found to inhibit COX-2 and iNOS activities at the cellular level.

Terminoside A inhibits the production of nitric oxide and decreases the levels of nitric oxide synthase in macrophages stimulated by lipopolysaccharide.

Cardioprotective Mechanisms

T. arjuna has been extensively studied in animal models to demonstrate cardioprotective properties, ranging from positive inotropic, hypolipidemic, coronary vasodilatory, and antioxidant effects to induction of stress protein in heart tissue. In preclinical models, T. arjuna exerts beneficial effects on left ventricular functions, myocardial remodeling, and autonomic control, possibly through maintaining endogenous antioxidant enzyme activities, inhibiting lipid peroxidation, and reducing cytokine levels.

Gastric and Mucosal Protection

Chebulinic acid protects the stomach by inhibiting the activity of the H⁺K⁺-ATP (proton pump) enzyme, indicating that it might represent an effective treatment to reduce the incidence of gastric ulcers. T. chebula significantly decreases overall gastric lesions and gastric juice volume while increasing gastric pH and mucus release in different physical and chemical stress-induced ulcer models.

Anticholinesterase and Neuroprotective Mechanisms

Studies have reported that gallic acid, ellagic acid, and tannic acid have exhibited antagonistic effects on both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in a dose-dependent manner. Different extracts of T. chebula have exhibited AChE inhibitory activity and NMDA receptor antagonism. Overall, T. chebula extracts and their constituents have been shown to possess AChE inhibitory, antioxidant, and anti-inflammatory effects, all of which are currently relevant to Alzheimer's disease research.

Antimicrobial Mechanisms

The antibacterial role of polyphenols involves interaction with microbial membrane proteins and inhibiting adherence of bacterial cells to tooth surfaces. Polyphenols also inhibit glucosyltransferase and amylase, which produce food-derived acids that can damage tooth enamel, and they inhibit tooth demineralization by interactions with organic matrices.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Disease — T. arjuna

T. arjuna bark decoction has been used in the Indian subcontinent for anginal pain, hypertension, congestive heart failure, and dyslipidemia, based on the observations of ancient physicians for centuries. Most studies, both experimental and clinical, have suggested that the crude drug possesses anti-ischemic, antioxidant, hypolipidemic, and antiatherogenic activities.

Chronic Heart Failure (CHF): A double-blind, parallel, randomized, placebo-controlled add-on clinical trial enrolled 100 CHF patients of New York Heart Association (NYHA) functional class II on standard pharmacotherapy with echocardiographic left ventricular ejection fraction (LVEF) ≤ 40%, randomized 1:1 to Arjuna extract 750 mg or matching placebo twice daily.

In an earlier double-blind crossover study of twelve patients with refractory chronic congestive heart failure (Class IV NYHA), related to idiopathic dilated cardiomyopathy (10 patients), previous myocardial infarction (1 patient), and peripartum cardiomyopathy (1 patient), patients received T. arjuna bark extract (500 mg every 8 hours) or matching placebo for 2 weeks each, separated by a 2-week washout period. T. arjuna, compared to placebo, was associated with improvement in symptoms and signs of heart failure and improvement in NYHA Class.

Stable Angina and Coronary Artery Disease: A number of clinical studies have reported beneficial effects in patients with chronic stable angina, endothelial dysfunction, heart failure, and even ischemic mitral regurgitation. However, identified lacunae include standardization of the drug, toxicity studies, pharmacological interaction data with other drugs, and the need for large multicenter randomized clinical trials before use by modern medicine is broadly acceptable.

Evidence Strength: For cardiovascular applications of T. arjuna, the body of evidence includes several small-to-medium-sized randomized controlled trials, predominantly from India, showing signals of benefit in CHF, angina, and dyslipidemia. However, trials are generally small, have short durations, and have not been replicated in large multicenter settings. Overall evidence is preliminary to moderate; data are promising but not sufficient to establish clinical recommendations by major regulatory bodies.

5.2 Hyperuricemia and Renal Biomarkers — T. bellirica and T. chebula

A randomized, double-blind, placebo- and positive-controlled clinical pilot study enrolled 110 eligible subjects with hyperuricemia and randomized them to five treatment groups: T. chebula 500 mg twice daily (BID), T. bellerica 250 mg BID, T. bellerica 500 mg BID, placebo BID, and febuxostat 40 mg once daily — for a duration of 24 weeks. Serum uric acid levels were measured at baseline and at the end of 4, 8, 12, 16, 20, and 24 weeks.

All active treatment groups showed a reduction in serum uric acid levels compared to baseline and placebo. Significant reduction in mean serum uric acid levels started as early as 4 weeks following treatment. The reduction of serum uric acid levels in the T. bellerica 500 mg group was nearly twice that of the T. chebula 500 mg group and T. bellerica 250 mg group at all time points. T. bellerica 500 mg reduced serum uric acid levels from 8.07 ± 0.87 to 5.78 ± 0.25 compared to febuxostat, which reduced serum uric acid levels from 8.53 ± 0.97 to 4.28 ± 0.67 (P < 0.001) at the end of 24 weeks. The efficacy of T. bellerica appeared to be dose-dependent. All formulations were well tolerated. T. bellerica has the potential for treating hyperuricemia as it was devoid of any serious adverse effects, though further studies are needed to confirm this potential.

A subsequent trial examined CKD patients specifically: 59 subjects were randomized to three groups — 40 mg once-daily febuxostat, 500 mg twice-daily and 1000 mg twice-daily of T. bellerica extract. Serum uric acid, creatinine levels, and estimated glomerular filtration rate were measured at baseline, 4, 8, 12, 16, 20, and 24 weeks. Biomarkers of oxidative stress, endothelial function, systemic inflammation, and platelet aggregation were evaluated at baseline, 4, 8, 12, and 24 weeks.

Evidence Strength: The hyperuricemia evidence represents randomized, double-blind, controlled pilot studies; results are encouraging but sample sizes are small and the field lacks independent replication. Evidence is preliminary.

5.3 Oral Health and Anticaries Activity — T. chebula

Since commonly available mouthwashes against oral pathogens exert adverse effects, the aqueous extract of T. chebula was investigated and proved to be an effective anticariogenic agent in research settings. The aim of the key study was to determine the antimicrobial properties of T. chebula against oral pathogens related to caries.

The antimicrobial effect of T. chebula against oral microbes showed a significant reduction between pre-rinse and post-rinse samples. Studies have investigated the anticaries mechanism of the ethanol extract of T. chebula on Streptococcus mutans, showing that it has effective anticaries activity through the inhibition of glucan formation and related gene expression, as well as antibacterial effects under low cytotoxic concentrations, suggesting potential application in oral hygiene products.

Studies have particularly highlighted the antimicrobial properties of T. chebula against Streptococcus mutans and Enterococcus faecalis, with extracts demonstrating stronger inhibitory effects than chlorhexidine in some in vitro models.

Evidence Strength: Oral health evidence consists largely of in vitro studies and small clinical pilot investigations. While findings are consistently positive against cariogenic bacteria, large-scale, long-term randomized controlled trials in humans are lacking. Evidence must be characterized as preliminary.

5.4 Gastrointestinal Applications

Terminalia bellirica and Terminalia chebula fruit decoctions, infusions, or pulp have been highlighted for their traditional uses to treat dysentery and chronic diarrhoea. The fruit is considered a digestive aid, liver stimulant, stomachic, gastrointestinal prokinetic agent, and mild laxative. The powder of T. chebula fruits has been used in chronic diarrhea.

Fractional inhibitory concentration studies revealed additive interactions between some conventional antibiotics and Terminalia plant extracts when used concurrently against gastrointestinal pathogens.

Evidence Strength: Gastrointestinal applications have a long and consistent record in traditional medicine and plausible mechanistic support from in vitro and animal studies (e.g., proton pump inhibition, motility effects). Direct, powered human clinical trials demonstrating efficacy are scarce; the evidence remains largely traditional and preclinical.

5.5 Antimicrobial and Antibiotic-Potentiating Activity

Terminalia species are reported to possess numerous biological properties, including antibacterial, antifungal, anti-inflammatory, antiviral, antiretroviral, antioxidant, and antiparasitic activity. Gallic acid and ethyl ester — two antibacterial compounds isolated from ethyl extract of fruits of T. chebula — act against Helicobacter pylori. Ether and alcohol extracts of T. chebula were tested against Helicobacter pylori.

The fruit and leaf extracts of T. ferdinandiana, an endemic Australian plant, have been found to possess strong antibacterial activity against various bacterial pathogens. The leaf extract has a potent growth inhibition effect on plantar malodor-producing bacteria.

Evidence Strength: Antimicrobial activities have been demonstrated consistently across multiple Terminalia species in in vitro assays. Clinical evidence in humans for infectious disease treatment is extremely limited; this remains a predominantly preclinical area of investigation.

5.6 Alzheimer's Disease and Neuroprotection

T. chebula is a medicinal plant reported to contain various biochemicals such as hydrolyzable tannins, phenolic compounds, and flavonoids. Reviewed scientific literature across PubMed, ScienceDirect, Scopus, and other databases found that T. chebula extracts and their constituents have AChE inhibitory, antioxidant, and anti-inflammatory effects — all of which are currently relevant to the treatment of Alzheimer's disease.

Evidence Strength: Neuroprotective and anti-Alzheimer's potential is entirely at the preclinical (in vitro and animal) stage. No clinical trials in humans have been reported. Evidence is speculative at this point.

5.7 Metabolic Effects — Lipid and Blood Sugar

T. bellirica extract significantly inhibited free radical-induced LDL oxidation in vitro. In THP-1 macrophages, T. bellirica extract treatment resulted in significant decreases in the mRNA expression of TNF-α, IL-1β, and lectin-like oxidized LDL receptor-1 (LOX-1).

The fruit of T. bellirica is used in Ayurvedic medicine to treat diabetes mellitus. Previous investigations of the effects of a hot water extract of T. bellirica fruit on obesity and insulin resistance in spontaneously obese type 2 diabetic mice showed that the extract enhanced the differentiation of 3T3-L1 cells to mature adipocytes and that one of the main active components identified was gallic acid.

Bioactive components of T. chebula including chebulic acid, gallic acid, protocatechuic acid, corilagin, chebulagic acid, chebulinic acid, 1,2,3,4,6-O-pentagalloylglucose, ellagic acid, and ethyl gallate have demonstrated anti-inflammatory, antiviral, and hypoglycemic properties.

Evidence Strength: Lipid and glucose effects have been documented in cell and animal models with some mechanistic clarity. Human clinical trials directly targeting type 2 diabetes or dyslipidemia as primary endpoints are limited, and the existing evidence is largely preclinical. No robust, definitive clinical evidence exists at this time.

6. Body Systems and Associated Health Areas

• Cardiovascular system: Historically T. arjuna has the most established association, with clinical data (though limited) for heart failure, angina, and endothelial function.
• Gastrointestinal system: T. chebula and T. bellirica are used across multiple traditions for digestion, bowel regularity, gastric ulcer prevention, and chronic diarrhea.
• Oral and dental health: T. chebula extracts have been studied against cariogenic bacteria and as mouthwash formulations.
• Renal system: T. bellirica has received recent clinical attention for hyperuricemia and creatinine lowering in CKD.
• Metabolic system: Anti-diabetic and lipid-modulating effects have been explored, particularly for T. bellirica and T. chebula, primarily at the preclinical level.
• Immune and inflammatory system: COX-2 and iNOS inhibition, cytokine modulation, and antioxidant activity are documented across multiple species.
• Neurological system: Preliminary data on AChE inhibition and neuroprotection by T. chebula constituents; no human trials.
• Antimicrobial: Active across bacteria and fungi in vitro; T. ferdinandiana and T. chebula most studied in this context.

7. Dosage Forms and Reported Dosages

The following dosages reflect those reported in clinical studies and traditional pharmacopoeial references; they are not recommendations:

• T. arjuna bark extract (cardiovascular): T. arjuna has most often been used by adults in doses of 500 mg by mouth three times daily for up to 3 months. T. arjuna bark extract 500 mg every 8 hours (reported treatment durations, 1 to 2 weeks) has been used in clinical studies evaluating effects on cardiovascular disorders.
• T. arjuna in CHF RCT: 750 mg twice daily of a standardized aqueous extract in the 100-patient randomized controlled CHF trial.
• T. bellirica for hyperuricemia: 250 mg BID and 500 mg BID (aqueous extract) for 24 weeks, compared to placebo and febuxostat 40 mg once daily.
• T. bellirica for CKD with hyperuricemia: 500 mg twice daily and 1000 mg twice daily of aqueous extract over 24 weeks.
• Ayurvedic Pharmacopoeia reference doses: According to the Ayurvedic Pharmacopoeia of India, the prescribed dose for T. chebula and T. bellirica is 3–6 g.

8. Safety Considerations and Interactions

General Tolerability

T. arjuna extracts are generally well tolerated. Adverse reactions similar to those with placebo — including constipation, headache, abdominal discomfort, and body ache — have been described. T. bellirica is possibly safe when used for up to 24 weeks and seems to be well-tolerated.

Gastrointestinal Adverse Effects

T. arjuna is generally considered safe for medicinal use; however, some studies have reported potential toxicity and side effects. The most commonly observed adverse effects include gastrointestinal disturbances such as diarrhea, nausea, and abdominal pain.

Hepatotoxicity Signals (Animal Data)

High doses may lead to hepatotoxicity, as indicated in certain animal studies that demonstrated increased liver enzymes. In rats, it was suggested that high amounts of T. arjuna extract could cause hepatotoxicity and hypothyroidism. These findings are from preclinical models; whether they translate to humans at therapeutic doses is not established.

Drug Interactions

T. arjuna may interact with other medications, particularly anticoagulants, due to its potential antithrombotic properties, which could increase the risk of bleeding. T. arjuna might change how quickly the liver breaks down certain medications, which could change the effects and side effects of those medications. This is of particular relevance given that in vitro data have shown modulation of hepatic cytochrome P450 enzymes (CYP3A4, CYP2D6, CYP2C9) by arjunic acid, arjunetin, and arjungenin.

Due to potential blood sugar-lowering effects, those with diabetes or those using anti-diabetic drugs should use caution. Terminalia's hypoglycemic and cardioprotective properties can interact with some drugs, particularly those used to treat diabetes and heart disease.

Cardiac Effects Requiring Supervision

The bark of the T. arjuna tree contains chemicals that might stimulate the heart. It might also have effects that lower cholesterol and blood pressure. Because of these direct cardiac actions, T. arjuna can affect the heart and should only be used under medical supervision.

Pregnancy and Lactation

Information regarding safety and efficacy in pregnancy and lactation is lacking.

Toxicology Data — T. chebula

In an acute-phase animal study, the safe dose was ≤5000 mg/kg for T. chebula extract. In the sub-acute phase, the LD₅₀ (95% CI) of T. chebula extract was determined to be 2754.436 (2438–3114) mg/kg. The highest dose of T. chebula extract induced few histopathological changes.

Species Confusability

It is important to note that different Terminalia species have distinct chemical profiles, pharmacological properties, safety signals, and traditional uses. Terminalia is a genus, not a single medicinal identity. Other species such as Terminalia arjuna and Terminalia bellirica have their own properties and should not be treated as interchangeable with Terminalia chebula. It is equally important not to confuse T. arjuna with T. chebula and T. bellirica, as these are not the same.

References

• Sagbo IJ et al. Plants of the Genus Terminalia: An Insight on Its Biological Potentials, Pre-Clinical and Clinical Studies. Frontiers in Pharmacology, 2020. PMC7578430
• Fan Y et al. The Genus Terminalia (Combretaceae): An Ethnopharmacological, Phytochemical and Pharmacological Review. Natural Products and Bioprospecting, 2019. PMC6872704
• Cock IE. The Medicinal Properties and Phytochemistry of Plants of the Genus Terminalia (Combretaceae). Inflammopharmacology, 2015. PubMed 26226895
• Maulik SK et al. Clinical efficacy of water extract of stem bark of Terminalia arjuna in patients of chronic heart failure: a double-blind, randomized controlled trial. Phytomedicine, 2016. PubMed 26988798
• Maulik SK, Talwar KK. Therapeutic potential of Terminalia arjuna in cardiovascular disorders. American Journal of Cardiovascular Drugs, 2012. PubMed 20874682
• Dwivedi S, Chopra D. Revisiting Terminalia arjuna — An Ancient Cardiovascular Drug. Journal of Traditional and Complementary Medicine, 2014. PubMed 25379463
• Bharani A et al. Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. International Journal of Cardiology, 1995. PubMed 7649665
• Usharani P et al. A randomized, double-blind, placebo- and positive-controlled clinical pilot study to evaluate the efficacy and tolerability of standardized aqueous extracts of Terminalia chebula and Terminalia bellerica in subjects with hyperuricemia. Clinical Pharmacology, 2016. PMC4922806
• Pingali U et al. A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in CKD subjects with hyperuricemia. BMC Complementary Medicine and Therapies, 2020. PMC7493401
• Nayak SS et al. Anti Cariogenic Effect of Terminalia Chebula. Journal of Clinical and Diagnostic Research, 2014. PMC4190794
• Bag A et al. The development of Terminalia chebula Retz. (Combretaceae) in clinical research. Asian Pacific Journal of Tropical Biomedicine, 2013. PMC3631759
• Choi BM et al. Terminalia bellirica Extract Inhibits Low-Density Lipoprotein Oxidation and Macrophage Inflammatory Response In Vitro. Evidence-Based Complementary and Alternative Medicine, 2016. PMC4931541
• Patel D et al. A Review on Potential Mechanisms of Terminalia chebula in Alzheimer's Disease. Advances in Pharmacological Sciences, 2016. PMC4749770
• Bhatt D et al. A comprehensive review on the diverse pharmacological perspectives of Terminalia chebula Retz. Heliyon, 2022.
• Kaur P et al. Phytochemical profile and pro-healthy properties of Terminalia chebula: A comprehensive review. International Journal of Food Properties, 2023.
• Comparative phytochemical profile and biological activity of three Terminalia species as alternative antimicrobial therapies. PMC, 2024. PMC11584580
• Pharmacokinetics of active compounds of a Terminalia chebula Retz. ethanolic extract after oral administration in rats using UPLC-MS/MS. PMC, 2023. PMC9880438
• Terminalia arjuna: An overview of its magical properties. PMC, 2025. PMC11993416
• Oral acute and sub-acute toxic effects of hydroalcoholic Terminalia chebula Retz and Achillea wilhelmsii extracts in BALB/c mice. PMC, 2019. PMC6870277
• Terminalia. Drugs.com Natural Products Database (Facts & Comparisons), 2026.
• Cock IE. The chemotherapeutic potential of Terminalia ferdinandiana: Phytochemistry and bioactivity. Pharmacognosy Reviews, 2012. PMC3358965
• Karthikeyan K et al. Terminalia arjuna enhances baroreflex sensitivity and myocardial function in isoproterenol-induced chronic heart failure rats. Journal of Cardiovascular Pharmacology, 2011. PubMed 21828283
• Phytochemical Analysis and Antimicrobial Activity of Terminalia bellirica and Terminalia chebula Fruit Extracts Against Gastrointestinal Pathogens. PMC, 2025. PMC11728670